Developing vaccines for infectious diseases including SARS-CoV-2
Official title: Task V25: PROCESS DEVELOPMENT FOR VACCINE CANDIDATES INCLUDING SARS-COV-2
Funded at Idt Biologika Gmbh · NIH-10168821 · Data updated 2026-11-12
This study is working on creating and improving vaccines to help protect people from infectious diseases like COVID-19, and it aims to make new vaccines that could also fight against bioterrorism threats, so everyone can benefit from better protection in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2020 |
| Award (this year) | $20,462 |
| NIH project number | 272201800011I-0-759302000001-1 |
| Project ID | NIH-10168821 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk for infectious diseases or those involved in clinical trials for new vaccines.
✕Less likely to help
Patients who are not at risk for infectious diseases or those who do not meet the criteria for clinical trial participation may not receive benefits from this research.
What this research studies
This research focuses on the development and optimization of vaccines and biologics to combat infectious diseases, including SARS-CoV-2. It involves planning and feasibility assessments, as well as the manufacturing of vaccine components in compliance with regulatory standards. The project aims to support the introduction of new vaccines against bioterrorism threats and emerging infectious diseases through rigorous testing and evaluation. Patients may benefit from the advancements in vaccine technology and the potential for new vaccines to be developed.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against infectious diseases, improving public health outcomes.
How similar studies have gone: Other research has shown success in developing vaccines using similar methodologies, indicating a promising approach to vaccine development.
Where this research is happening
-
Idt Biologika Gmbh
Dessau-Rosslau, Germany Active
Researchers
- Principal investigator: Neubert, Andreas — Idt Biologika Gmbh
- Study coordinator: Neubert, Andreas
Related research
Other NIH-funded projects on the same topics.
-
How COVID-19 infection and genes may influence memory and dementia risk
This study looks at how getting COVID-19 and a person’s genes together affect the chance of developing memory problems and Alzheimer’s disease later in life.
-
Understanding flu and COVID-19 vaccine responses in people and in the lab
Researchers at Stanford explore how flu and COVID-19 vaccines work in people and in lab tests to improve protection for adults.
-
Oral small molecule inhibitors to block SARS-CoV-2 RNA replication
A Stanford-led project tests a pill that could stop SARS-CoV-2 and related viruses from copying their RNA inside infected cells.
-
Outpatient antiviral cocktails to fight SARS-CoV-2 and future RNA viruses
Researchers at Stanford are developing outpatient antiviral cocktails that could be used easily outside the hospital to treat COVID-19 and future RNA virus infections.
-
Inhibitors for SARS-CoV-2 Proteases to Block Viral Replication
A patient-facing program aims to discover and optimize small molecules that block key SARS-CoV-2 enzymes, potentially reducing viral replication.
-
How different COVID-19 vaccines shape immune responses
This project compares immune reactions after mRNA and adenoviral COVID-19 vaccines to learn how long protection lasts and why some people get breakthrough infections or side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.